Ophthalmology Deals Are Up 1100% in 2026 — Here's the Data

Ophthalmology deal activity jumped 1100% in the six months ending September 2026 compared to the prior half-year — from 1 tracked deal to 12. That's not a rounding error on a small base; it's a structural repricing of an entire therapeutic area. After years of treating retinal and ocular assets as second-tier pipeline filler, Big Pharma has decided — almost simultaneously — that ophthalmology is a must-own franchise. The trigger: durable biologics, gene therapies approaching commercialization, and a $5.6 billion signal from Biogen that complement-driven retinal disease is worth paying full freight for.

The Data — Ophthalmology Deal Activity, Period over Period

The prior six-month period — September 2025 through March 2026 — registered a single ophthalmology deal of note. The subsequent period delivered 12, including two transactions with total deal values exceeding $1 billion. You can benchmark these figures against historical norms using Deal Benchmarks on the Ambrosia platform.

What's Driving the Trend

Three forces converged to produce this ophthalmology licensing 2026 wave. First, the anti-VEGF market — long dominated by Regeneron's Eylea — is fracturing. Biosimilar entrants have compressed margins on legacy anti-VEGF franchises, forcing incumbents to look beyond VEGF inhibition for differentiated retinal assets. Complement inhibition, gene therapy, and novel mechanisms in dry AMD and geographic atrophy (GA) are the new high ground. Apellis's Syfovre demonstrated that GA is a commercially viable indication, and Biogen's $5.6B acquisition is an explicit bet that the complement pathway in retinal disease has blockbuster-scale durability beyond what the Street currently models.

Second, ocular gene therapy has crossed the clinical derisking threshold that Big Pharma requires. REGENXBIO's AAV-based platform attracted AbbVie. MeiraGTx's gene therapy portfolio secured a $130M upfront from Johnson & Johnson. These aren't speculative options on preclinical programs — they're deals built on late-stage clinical data showing durable, one-time-treatment efficacy in inherited retinal diseases and wet AMD. The manufacturing bottleneck that plagued early gene therapy is narrowing, and pharma companies that waited for process maturity are now rushing in.

Third, capital allocation strategy at the top 20 pharma companies has shifted. Oncology multiples are stretched. Immunology is crowded with IL-23 and TL1A assets. Ophthalmology, by contrast, offers concentrated patient populations, clear regulatory endpoints, specialist-driven prescribing, and — critically — pricing power. Payers have historically accepted premium pricing for vision-saving therapies. BD teams at AbbVie, Merck, and J&J are reading the same map: ophthalmology is one of the few remaining therapeutic areas where a well-timed deal can build a $2B+ franchise without competing against 15 other approved agents.

Notable Deals

Biogen–Apellis ($5.6B): This is the anchor deal of the cycle. Biogen paid the full enterprise value — no milestone-heavy structure, no royalty-only deal. The $5.6B price implies Biogen projects Syfovre and the broader complement ophthalmology portfolio can generate peak annual revenues north of $3B. That's aggressive, but it reflects Biogen's need to diversify beyond neurology and its willingness to pay a control premium to do it. For ophthalmology deal trends 2026, this transaction single-handedly resets valuation comps.

REGENXBIO–AbbVie: AbbVie's second ophthalmology move in three months (following the Aldeyra deal in April). REGENXBIO's RGX-314 gene therapy for wet AMD offers AbbVie a durable, one-time-treatment alternative to chronic anti-VEGF injections. Undisclosed terms suggest a complex structure — likely a significant upfront with clinical and commercial milestones — but the strategic logic is clear: AbbVie is building an ophthalmology franchise from scratch, using M&A velocity to compress a decade of organic pipeline work into 18 months.

MeiraGTx–J&J ($130M upfront): The $130M upfront is notable for a gene therapy company at MeiraGTx's stage. J&J is paying for manufacturing expertise as much as pipeline. MeiraGTx's vertically integrated AAV manufacturing gives J&J supply chain control that most gene therapy licensors can't offer. This deal will become a reference point for gene therapy licensing valuations through year-end. Use Solidus to compare the MeiraGTx terms against similar-stage ophthalmology transactions.

EyeBio–Merck and AbbVie–Aldeyra: Both deals, struck within days of each other in early April, signal that the second wave of ophthalmology deal trends 2026 extends beyond complement and gene therapy. Merck's acquisition of EyeBio brings a bispecific antibody approach to retinal disease, while AbbVie's deal with Aldeyra targets dry eye and ocular inflammation — a market segment adjacent to retina but with distinct commercial dynamics. The clustering of these deals in a single week wasn't coincidental; once Apellis was rumored to be in play, competing BD teams accelerated timelines to avoid being locked out of a shrinking target pool.

What This Means for BD Teams Right Now

If you're selling an ophthalmology asset: This is a seller's market, and the window is open now. The Biogen-Apellis deal at full enterprise value with no milestone discount sets a ceiling that other buyers will resist but cannot ignore. Phase 2+ retinal assets with differentiated mechanisms — complement, gene therapy, bispecific — should be running competitive processes immediately. Upfront-to-TDV ratios in ophthalmology licensing 2026 are compressing, meaning buyers are putting more cash upfront rather than back-loading into milestones. That benefits licensors who need non-dilutive capital now.

If you're buying: Move fast or overpay later. The target pool in ophthalmology is finite — there are perhaps 15–20 clinical-stage companies with genuinely differentiated retinal or ocular assets, and five of them transacted in the last six months. Every deal removes a target and increases the scarcity premium on remaining assets. AbbVie's strategy of executing two deals in rapid succession is the right playbook: build franchise scale before competitors bid up the last remaining targets. Structurally, expect sellers to push for higher upfronts and lower milestone dependency. Royalty-only structures are effectively dead in this market for anything past Phase 1.

Deal structure insight: The Biogen-Apellis structure — full acquisition, no contingent value — will pull other deal formats toward higher certainty of payment. Licensing deals that might have been structured as $50M upfront plus $500M in milestones six months ago will now see sellers demanding $150M+ upfront with accelerated near-term milestones. BD teams should model their offers against the current ophthalmology benchmarks available on the Deal Benchmarks page to avoid underbidding in a competitive process.

Benchmark your deal against current market rates — run your term sheet through the Ambrosia calculator to see how your upfront, milestones, and royalty structure compares to the 12 ophthalmology deals closed in the last six months.